Alexander Michel
Overview
Explore the profile of Alexander Michel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
515
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Butler O, Raisi-Estabragh Z, Han Y, Frenz A, Harz C, Kelle S, et al.
Open Heart
. 2024 Nov;
11(2.
PMID: 39521611
Background: Previous research has suggested a heightened risk of acute myocarditis after COVID-19 infection. However, it is not clear from existing work whether this risk is higher than would be...
2.
Okami S, Lecomte C, Raad H, Aguila M, Mohrova Z, Takeichi M, et al.
Sci Rep
. 2024 Oct;
14(1):24193.
PMID: 39406947
No abstract available.
3.
Endrikat J, Ullmann A, Gerlinger C, Bhatti A, Lengsfeld P, Michel A
Br J Radiol
. 2024 Sep;
97(1164):2004-2014.
PMID: 39312632
Objective: To analyse the potential impact of patients' sex, race, and region/country on the risk of hypersensitivity reactions after intra-venous or intra-arterial administration of iopromide. Methods: Two analyses were performed....
4.
Jain T, Prinz B, Marker A, Michel A, Reichel K, Czepczor V, et al.
MAbs
. 2024 Jul;
16(1):2384104.
PMID: 39083118
In vitro assessments for the prediction of pharmacokinetic (PK) behavior of biotherapeutics can help identify corresponding liabilities significantly earlier in the discovery timeline. This can minimize the need for extensive...
5.
Okami S, Ohlmeier C, Takeichi M, Aguila M, Holl K, Michel A, et al.
J Clin Med
. 2024 Jun;
13(11).
PMID: 38892932
Vericiguat was developed to treat patients with heart failure (HF). Currently, limited data are available to characterize vericiguat-treated patients in real-world clinical settings. This retrospective cohort study was done using...
6.
Okami S, Lecomte C, Raad H, Aguila M, Mohrova Z, Takeichi M, et al.
Sci Rep
. 2024 Apr;
14(1):9095.
PMID: 38643208
Currently, the utilization patterns of medications for heart failure (HF) after worsening HF events remain unelucidated in Japan. Here, we conducted a retrospective cohort study evaluating the changes in HF...
7.
Michel A, Lecomte C, Ohlmeier C, Raad H, Basedow F, Haeckl D, et al.
Am J Cardiovasc Drugs
. 2024 Apr;
24(3):409-418.
PMID: 38573461
Background: Data are limited regarding guideline-directed medical therapy (GDMT) treatment patterns in patients with worsening heart failure (HF). Methods: We used administrative claims databases in Germany and the USA to...
8.
Kerwagen F, Ohlmeier C, Evers T, Herrmann S, Bayh I, Michel A, et al.
Eur J Clin Pharmacol
. 2024 Mar;
80(6):931-940.
PMID: 38472389
Purpose: Vericiguat reduced clinical endpoints in patients experiencing worsening heart failure in clinical trials, but its implementation outside trials is unclear. Methods: This retrospective analysis of longitudinally collected data was...
9.
Zografos L, Andrews E, Wolin D, Calingaert B, Davenport E, Michel A, et al.
Pharmaceut Med
. 2023 Dec;
38(1):63-73.
PMID: 38049618
Background: Materials have been distributed in the European Union to inform physicians on the safe use of intravitreal aflibercept (IVT-AFL) as part of the risk-minimization plan for IVT-AFL. Objective: We...
10.
Spanig S, Michel A, Heider D
BioData Min
. 2023 Mar;
16(1):10.
PMID: 36927546
Background: Owing to the rising levels of multi-resistant pathogens, antimicrobial peptides, an alternative strategy to classic antibiotics, got more attention. A crucial part is thereby the costly identification and validation....